Why the study?
Does high platelet CD62p expression predict myocardial damage and 30-day adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary coronary stenting?
Does high platelet CD62p expression predict myocardial damage and 30-day adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary coronary stenting?
Initial platelet CD62p expression is a significant biomarker for predicting the extent of myocardial damage and 30-day adverse clinical outcomes in patients with ST-elevation AMI undergoing primary stenting.
No takes yet. Share an insight, caveat, or question.
High CD62p expression may support biomarker use for 30-day MACO risk in STEMI stenting; leaves open prospective validation before clinical adoption.
Yip et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: